Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Joseph Saseen

Concepts (451)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
22
2022
387
4.650
 Why?
Pharmacists
17
2023
238
3.070
 Why?
Hypertension
22
2021
1203
2.640
 Why?
Antihypertensive Agents
13
2021
437
2.350
 Why?
Cardiovascular Diseases
18
2022
1798
2.150
 Why?
Atherosclerosis
5
2022
345
2.090
 Why?
Students, Pharmacy
7
2018
99
2.040
 Why?
Cholesterol, LDL
11
2021
316
1.950
 Why?
Hypercholesterolemia
7
2021
93
1.710
 Why?
Educational Measurement
5
2018
289
1.640
 Why?
Hypolipidemic Agents
8
2021
86
1.630
 Why?
Professional Role
7
2020
153
1.550
 Why?
Education, Pharmacy
7
2018
130
1.530
 Why?
Practice Guidelines as Topic
13
2020
1440
1.380
 Why?
Medication Therapy Management
5
2018
72
1.350
 Why?
Anticholesteremic Agents
7
2021
130
1.330
 Why?
Dyslipidemias
7
2016
162
1.310
 Why?
Ambulatory Care
9
2018
482
1.240
 Why?
Cholesterol
5
2020
373
1.230
 Why?
Calcium Channel Blockers
7
2015
117
1.220
 Why?
Managed Care Programs
4
2014
135
1.150
 Why?
Societies, Pharmaceutical
7
2017
28
1.060
 Why?
Practice Patterns, Physicians'
5
2023
1200
1.040
 Why?
Hydrochlorothiazide
2
2014
11
1.030
 Why?
Chlorthalidone
2
2014
7
1.030
 Why?
Arthritis, Gouty
2
2016
14
1.000
 Why?
Pharmaceutical Services
5
2020
79
1.000
 Why?
Blood Pressure
11
2021
1664
0.980
 Why?
Humans
125
2023
118974
0.980
 Why?
Urinary Tract Infections
2
2023
136
0.950
 Why?
Anti-Inflammatory Agents, Non-Steroidal
5
2018
304
0.950
 Why?
Adrenergic beta-Antagonists
4
2014
301
0.910
 Why?
Education, Pharmacy, Graduate
4
2017
21
0.910
 Why?
Pharmacy Residencies
3
2018
11
0.910
 Why?
Retrospective Studies
34
2023
12978
0.890
 Why?
American Heart Association
4
2020
270
0.890
 Why?
Diabetes Mellitus
4
2023
942
0.880
 Why?
Clinical Competence
4
2018
951
0.870
 Why?
Blood Glucose
4
2017
1939
0.860
 Why?
Hypoglycemic Agents
4
2014
1032
0.810
 Why?
Dicarboxylic Acids
1
2021
6
0.800
 Why?
Coronary Artery Disease
3
2021
647
0.800
 Why?
Diuretics
4
2014
76
0.800
 Why?
Serotonin 5-HT1 Receptor Agonists
1
2020
3
0.790
 Why?
Preceptorship
2
2018
63
0.790
 Why?
Gout
3
2020
57
0.790
 Why?
Diabetes Mellitus, Type 2
7
2022
2174
0.780
 Why?
Evidence-Based Medicine
14
2018
693
0.780
 Why?
Angiotensin-Converting Enzyme Inhibitors
5
2011
195
0.770
 Why?
Drug Prescriptions
2
2020
248
0.770
 Why?
Teaching
3
2018
236
0.750
 Why?
Aged
33
2023
19657
0.740
 Why?
Migraine Disorders
1
2020
79
0.720
 Why?
Middle Aged
37
2023
27617
0.710
 Why?
Muscular Diseases
2
2015
107
0.710
 Why?
Emergency Service, Hospital
2
2020
1865
0.710
 Why?
Primary Health Care
8
2023
1560
0.700
 Why?
Health Benefit Plans, Employee
2
2017
20
0.680
 Why?
Drug Therapy
2
2017
76
0.670
 Why?
Proton Pump Inhibitors
1
2019
98
0.640
 Why?
Fatty Acids
1
2021
407
0.640
 Why?
Acetaminophen
3
2007
244
0.630
 Why?
Insurance Coverage
2
2011
208
0.630
 Why?
Lipids
2
2020
607
0.610
 Why?
Simvastatin
3
2015
65
0.610
 Why?
Faculty, Pharmacy
1
2017
17
0.590
 Why?
Schools, Pharmacy
1
2017
52
0.590
 Why?
Research
2
2017
411
0.570
 Why?
Population Health
1
2017
46
0.560
 Why?
HIV
1
2017
210
0.560
 Why?
Adult
31
2021
31512
0.550
 Why?
Female
47
2020
61565
0.550
 Why?
Cardiology
4
2018
272
0.550
 Why?
Perception
1
2018
314
0.540
 Why?
Heart Failure
3
2023
1969
0.540
 Why?
Anti-Retroviral Agents
1
2017
208
0.530
 Why?
Hyperlipidemias
5
2018
128
0.530
 Why?
Male
42
2020
57801
0.530
 Why?
Antipsychotic Agents
1
2017
193
0.530
 Why?
Monitoring, Physiologic
1
2017
272
0.520
 Why?
Aged, 80 and over
13
2020
6561
0.520
 Why?
Faculty, Medical
1
2017
252
0.510
 Why?
Poverty
2
2008
444
0.500
 Why?
Angiotensin II Type 1 Receptor Blockers
2
2013
32
0.490
 Why?
Primary Prevention
2
2021
185
0.490
 Why?
Program Evaluation
3
2017
845
0.480
 Why?
United States
22
2022
12555
0.480
 Why?
Analgesics, Non-Narcotic
2
2007
116
0.480
 Why?
Gout Suppressants
2
2020
33
0.470
 Why?
Self Report
1
2017
699
0.470
 Why?
Tetrazoles
1
2013
32
0.470
 Why?
Drug Therapy, Combination
12
2020
965
0.470
 Why?
Ezetimibe
4
2021
23
0.460
 Why?
Analgesics, Opioid
1
2020
794
0.450
 Why?
Gemfibrozil
3
2016
10
0.450
 Why?
Curriculum
6
2018
910
0.450
 Why?
Osteoarthritis
2
2006
176
0.440
 Why?
Adrenal Cortex Hormones
2
2016
521
0.440
 Why?
Anti-Arrhythmia Agents
2
2003
113
0.440
 Why?
Venoms
1
2012
33
0.430
 Why?
Imidazoles
1
2013
232
0.430
 Why?
Electronic Health Records
5
2018
829
0.420
 Why?
Treatment Outcome
16
2021
9342
0.420
 Why?
Lipoprotein(a)
2
2022
49
0.410
 Why?
Health Expenditures
5
2017
174
0.410
 Why?
Kidney
1
2019
1353
0.400
 Why?
Colorado
12
2023
4196
0.400
 Why?
Problem-Based Learning
3
2017
82
0.400
 Why?
Health Resources
1
2012
132
0.390
 Why?
Medicare Part D
1
2011
25
0.380
 Why?
Risk Assessment
11
2022
3057
0.380
 Why?
Renal Insufficiency, Chronic
1
2017
589
0.370
 Why?
Arthritis, Rheumatoid
3
2009
989
0.370
 Why?
Risk Factors
16
2022
9000
0.370
 Why?
Insurance Claim Review
3
2017
67
0.360
 Why?
Azetidines
2
2008
29
0.360
 Why?
Antibodies, Monoclonal
4
2020
1284
0.330
 Why?
Antirheumatic Agents
2
2009
254
0.330
 Why?
Clinical Trials as Topic
8
2017
969
0.330
 Why?
Age Factors
5
2017
2995
0.320
 Why?
Venous Thromboembolism
2
2022
234
0.320
 Why?
Community Health Centers
2
2018
57
0.320
 Why?
Cohort Studies
10
2020
5116
0.320
 Why?
Drug Costs
2
2006
94
0.310
 Why?
HIV Infections
2
2023
2459
0.310
 Why?
Weight Loss
3
2012
655
0.300
 Why?
Verapamil
2
1997
32
0.300
 Why?
Young Adult
9
2021
10793
0.300
 Why?
Kidney Failure, Chronic
2
2010
516
0.290
 Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2007
44
0.290
 Why?
Family Practice
4
2015
438
0.290
 Why?
Peptides
1
2012
879
0.290
 Why?
Certification
2
2006
99
0.290
 Why?
Liver Diseases, Alcoholic
1
2007
87
0.290
 Why?
Drug Interactions
3
2017
352
0.290
 Why?
Tablets
1
2006
35
0.290
 Why?
Randomized Controlled Trials as Topic
7
2007
1244
0.290
 Why?
Renal Dialysis
1
2010
378
0.290
 Why?
Aspirin
2
2008
334
0.280
 Why?
Cyclooxygenase 2 Inhibitors
1
2006
20
0.280
 Why?
Drug Compounding
1
2006
90
0.280
 Why?
Lipoproteins
1
2007
162
0.280
 Why?
Patient Care
3
2017
105
0.270
 Why?
Insurance, Health
4
2015
244
0.270
 Why?
Chemical and Drug Induced Liver Injury
2
2007
136
0.270
 Why?
Sodium Chloride, Dietary
1
2006
49
0.270
 Why?
Benzothiadiazines
1
2005
3
0.260
 Why?
Sodium Chloride Symporter Inhibitors
1
2005
13
0.260
 Why?
Ambulatory Care Facilities
2
2017
218
0.260
 Why?
Blood Pressure Determination
3
2018
133
0.260
 Why?
Gastrointestinal Hemorrhage
1
2006
109
0.260
 Why?
Guideline Adherence
3
2020
523
0.260
 Why?
Societies, Medical
3
2019
703
0.260
 Why?
Platelet Aggregation Inhibitors
1
2008
402
0.250
 Why?
Brain Ischemia
1
2008
310
0.250
 Why?
Drug Labeling
3
2015
45
0.250
 Why?
Glomerular Filtration Rate
2
2019
683
0.250
 Why?
Bronchiolitis, Viral
1
2004
10
0.250
 Why?
Quality Assurance, Health Care
1
2006
325
0.240
 Why?
Patient-Centered Care
3
2015
497
0.240
 Why?
Incidence
3
2023
2424
0.230
 Why?
Life Style
1
2006
430
0.230
 Why?
Off-Label Use
2
2015
48
0.230
 Why?
Hormone Replacement Therapy
1
2004
80
0.230
 Why?
Contraceptive Agents
1
2004
57
0.230
 Why?
Medroxyprogesterone
1
2003
10
0.230
 Why?
Progesterone Congeners
1
2003
15
0.230
 Why?
Quality Indicators, Health Care
1
2005
295
0.220
 Why?
Estrogens, Conjugated (USP)
1
2003
34
0.220
 Why?
C-Reactive Protein
1
2005
360
0.220
 Why?
Epinephrine
1
2004
167
0.220
 Why?
Faculty
2
2018
135
0.220
 Why?
Heart Conduction System
1
2003
81
0.220
 Why?
Tumor Necrosis Factor-alpha
1
2007
1171
0.220
 Why?
Contraception
1
2004
118
0.220
 Why?
Program Development
2
2017
357
0.210
 Why?
Bronchodilator Agents
1
2004
253
0.210
 Why?
Death, Sudden, Cardiac
1
2003
166
0.210
 Why?
Estrogen Replacement Therapy
1
2003
117
0.210
 Why?
Antiphospholipid Syndrome
1
2021
29
0.200
 Why?
Attitude to Health
1
2005
410
0.200
 Why?
Communicable Diseases
1
2023
132
0.200
 Why?
Atenolol
2
2014
6
0.200
 Why?
Pre-Exposure Prophylaxis
1
2023
174
0.200
 Why?
Text Messaging
1
2023
155
0.200
 Why?
Transition to Adult Care
1
2022
58
0.190
 Why?
Drug Tolerance
1
2021
78
0.190
 Why?
Patient Care Team
4
2022
521
0.190
 Why?
Vasodilator Agents
1
2003
328
0.190
 Why?
Adolescent
7
2020
18480
0.190
 Why?
Xanthine Oxidase
2
2020
80
0.190
 Why?
Costs and Cost Analysis
3
2014
202
0.190
 Why?
Diabetic Nephropathies
1
2004
289
0.190
 Why?
Public Health Administration
1
2021
78
0.190
 Why?
Dipyrone
1
1999
1
0.180
 Why?
Methenamine
1
2019
5
0.180
 Why?
Pharmacy Service, Hospital
2
2013
86
0.180
 Why?
Appetite Stimulants
1
1999
2
0.180
 Why?
Dose-Response Relationship, Drug
4
2014
1945
0.180
 Why?
HIV Wasting Syndrome
1
1999
4
0.180
 Why?
Diltiazem
2
1996
22
0.180
 Why?
Anti-Infective Agents, Urinary
1
2019
14
0.180
 Why?
Anabolic Agents
1
1999
12
0.180
 Why?
Nifedipine
2
1996
29
0.180
 Why?
Drug and Narcotic Control
1
1999
28
0.180
 Why?
Stroke
1
2008
1047
0.180
 Why?
Heart Rate
1
2003
729
0.170
 Why?
Proprotein Convertase 9
1
2019
60
0.170
 Why?
Protons
1
2019
79
0.170
 Why?
Internship, Nonmedical
3
2011
17
0.170
 Why?
Atrial Fibrillation
1
2003
338
0.170
 Why?
Secondary Prevention
2
2021
227
0.170
 Why?
Training Support
1
2018
24
0.160
 Why?
Federal Government
1
2018
26
0.160
 Why?
Expert Testimony
2
2017
56
0.160
 Why?
Guidelines as Topic
2
2019
262
0.160
 Why?
Thrombosis
1
2021
309
0.160
 Why?
Health Services
2
2009
110
0.160
 Why?
Acquired Immunodeficiency Syndrome
1
1999
224
0.160
 Why?
Risk
2
2017
853
0.160
 Why?
Medically Underserved Area
1
2018
87
0.160
 Why?
Anticoagulants
4
2022
559
0.150
 Why?
Severity of Illness Index
3
2019
2674
0.150
 Why?
Models, Econometric
1
2017
34
0.150
 Why?
Quality of Health Care
2
2017
586
0.150
 Why?
Vulnerable Populations
1
2018
147
0.150
 Why?
Anti-HIV Agents
1
2023
664
0.150
 Why?
United States Food and Drug Administration
2
2015
175
0.150
 Why?
Warfarin
3
2021
139
0.140
 Why?
Colchicine
1
2016
27
0.140
 Why?
Point-of-Care Systems
1
2018
151
0.140
 Why?
Protease Inhibitors
1
2017
102
0.140
 Why?
Alcoholism
1
2003
717
0.140
 Why?
Chronic Disease
3
2013
1636
0.140
 Why?
Comorbidity
4
2016
1527
0.140
 Why?
Surveys and Questionnaires
2
2018
4708
0.130
 Why?
Amlodipine
1
2015
8
0.130
 Why?
Pharmacovigilance
1
2015
13
0.130
 Why?
Exercise
1
2006
1657
0.130
 Why?
Patient Education as Topic
2
2012
699
0.130
 Why?
Hyperuricemia
1
2016
134
0.130
 Why?
Education, Medical, Undergraduate
1
2017
199
0.130
 Why?
Liver
1
2003
1816
0.130
 Why?
Systole
1
2014
168
0.120
 Why?
Ethanolamines
1
2014
18
0.120
 Why?
Benzopyrans
1
2014
25
0.120
 Why?
Nebivolol
1
2014
9
0.120
 Why?
Metoprolol
1
2014
37
0.120
 Why?
Follow-Up Studies
3
2016
4596
0.120
 Why?
Risk Reduction Behavior
3
2022
199
0.120
 Why?
Losartan
1
2013
10
0.120
 Why?
Carbazoles
1
2014
80
0.120
 Why?
Valsartan
1
2013
22
0.120
 Why?
Propanolamines
1
2014
93
0.120
 Why?
Drug Substitution
1
2013
46
0.120
 Why?
Medicaid
1
2017
411
0.120
 Why?
Biphenyl Compounds
1
2013
52
0.120
 Why?
Valine
1
2013
77
0.110
 Why?
Uric Acid
1
2016
354
0.110
 Why?
Antidepressive Agents, Second-Generation
2
2004
37
0.110
 Why?
Patient Acceptance of Health Care
2
2012
687
0.110
 Why?
Biomarkers
5
2018
3588
0.110
 Why?
Telemedicine
1
2021
664
0.110
 Why?
Socioeconomic Factors
1
2017
1129
0.110
 Why?
Fibric Acids
1
2012
2
0.110
 Why?
Contraindications
1
2012
86
0.110
 Why?
Decision Support Systems, Clinical
1
2015
178
0.110
 Why?
Drug Combinations
2
2016
291
0.110
 Why?
Internship and Residency
2
2017
1001
0.110
 Why?
Reproducibility of Results
3
2005
2874
0.110
 Why?
Double-Blind Method
4
2003
1687
0.100
 Why?
Age Distribution
1
2012
362
0.100
 Why?
Consensus
3
2018
534
0.100
 Why?
Sex Factors
1
2017
1781
0.100
 Why?
Annual Reports as Topic
1
2010
5
0.100
 Why?
Professional Staff Committees
1
2010
12
0.100
 Why?
Vascular Endothelial Growth Factor A
1
2014
527
0.100
 Why?
Acute Kidney Injury
1
2018
709
0.100
 Why?
Financing, Personal
1
2011
27
0.100
 Why?
Interpersonal Relations
1
2014
345
0.100
 Why?
Insurance Benefits
1
2010
10
0.100
 Why?
Insurance, Pharmaceutical Services
1
2010
21
0.100
 Why?
Pharmacy
1
2010
30
0.090
 Why?
Creatinine
1
2012
491
0.090
 Why?
Nutrition Surveys
2
2021
233
0.090
 Why?
Drug Utilization Review
2
2006
60
0.090
 Why?
Hypoglycemia
1
2014
400
0.090
 Why?
Analysis of Variance
1
2012
1293
0.090
 Why?
Hyperlipoproteinemia Type II
2
2019
26
0.090
 Why?
Dipyridamole
1
2008
27
0.080
 Why?
Prescription Drugs
1
2010
113
0.080
 Why?
Ezetimibe, Simvastatin Drug Combination
1
2008
1
0.080
 Why?
Fluorobenzenes
1
2008
13
0.080
 Why?
Rosuvastatin Calcium
1
2008
19
0.080
 Why?
Patient Compliance
3
2008
537
0.080
 Why?
Ticlopidine
1
2008
61
0.080
 Why?
Drug Administration Schedule
2
2007
736
0.080
 Why?
Abatacept
1
2007
42
0.080
 Why?
Ischemic Attack, Transient
1
2008
62
0.080
 Why?
Hemorrhage
2
2022
623
0.080
 Why?
Health Knowledge, Attitudes, Practice
1
2016
1185
0.080
 Why?
Proportional Hazards Models
1
2011
1125
0.080
 Why?
Dipeptidyl Peptidase 4
1
2007
12
0.080
 Why?
Antibodies, Monoclonal, Murine-Derived
1
2007
82
0.080
 Why?
Adamantane
1
2007
16
0.080
 Why?
Timolol
1
2007
14
0.080
 Why?
Propranolol
1
2007
54
0.070
 Why?
Contraception, Postcoital
1
2007
6
0.070
 Why?
Pyrrolidines
1
2007
57
0.070
 Why?
Accreditation
1
2007
87
0.070
 Why?
Community Pharmacy Services
1
2007
46
0.070
 Why?
Levonorgestrel
1
2007
32
0.070
 Why?
Rituximab
1
2007
155
0.070
 Why?
Specialty Boards
1
2006
39
0.070
 Why?
Immunoconjugates
1
2007
89
0.070
 Why?
Nitriles
1
2007
155
0.070
 Why?
Anti-Ulcer Agents
1
2006
16
0.070
 Why?
Cost Savings
1
2006
77
0.070
 Why?
Medication Errors
1
2006
92
0.070
 Why?
Safety Management
1
2006
109
0.070
 Why?
Delivery of Health Care
3
2022
867
0.070
 Why?
Pyrimidines
1
2008
382
0.060
 Why?
Case Management
1
2005
63
0.060
 Why?
Efficiency, Organizational
1
2005
126
0.060
 Why?
Sulfonamides
1
2008
445
0.060
 Why?
Pharmaceutical Preparations
1
2006
167
0.060
 Why?
Child, Preschool
2
2017
9491
0.060
 Why?
Nephrology
1
2005
50
0.060
 Why?
Benchmarking
1
2005
172
0.060
 Why?
Longitudinal Studies
1
2011
2513
0.060
 Why?
Rhabdomyolysis
1
2003
18
0.060
 Why?
Professional-Patient Relations
1
2005
147
0.060
 Why?
Coronary Disease
2
2003
356
0.060
 Why?
Medicare
1
2009
663
0.060
 Why?
Amiodarone
1
2003
24
0.060
 Why?
Albuterol
1
2004
104
0.060
 Why?
Enzyme Inhibitors
1
2007
827
0.060
 Why?
Meta-Analysis as Topic
1
2004
164
0.060
 Why?
Disease Susceptibility
1
2005
331
0.060
 Why?
Antineoplastic Agents
1
2014
1974
0.060
 Why?
Liver Function Tests
1
2003
107
0.060
 Why?
Endpoint Determination
1
2003
69
0.050
 Why?
Sodium Potassium Chloride Symporter Inhibitors
1
2022
12
0.050
 Why?
Nocebo Effect
1
2022
9
0.050
 Why?
Cyclohexanols
1
2002
10
0.050
 Why?
Delivery of Health Care, Integrated
2
2018
233
0.050
 Why?
Vaginal Diseases
1
2002
17
0.050
 Why?
Physician-Patient Relations
1
2006
490
0.050
 Why?
Women's Health
1
2004
274
0.050
 Why?
Information Dissemination
1
2004
210
0.050
 Why?
Reminder Systems
1
2023
163
0.050
 Why?
Sodium
1
2022
200
0.050
 Why?
Acute Disease
1
2004
940
0.050
 Why?
Vitamin K 1
1
2000
2
0.050
 Why?
Postmenopause
1
2003
305
0.050
 Why?
Kidney Diseases
1
2005
439
0.050
 Why?
Symptom Flare Up
1
2020
41
0.050
 Why?
Liver Diseases
1
2003
282
0.050
 Why?
Antifibrinolytic Agents
1
2000
44
0.050
 Why?
Aftercare
1
2022
194
0.050
 Why?
Health Plan Implementation
1
2021
133
0.050
 Why?
Medical Audit
2
2013
75
0.050
 Why?
Rivaroxaban
1
2021
208
0.050
 Why?
Neoplasms
1
2014
2179
0.050
 Why?
Predictive Value of Tests
1
2005
1868
0.050
 Why?
Patient Satisfaction
1
2004
610
0.040
 Why?
Europe
1
2020
356
0.040
 Why?
Administration, Oral
1
2021
756
0.040
 Why?
Ibuprofen
1
1999
76
0.040
 Why?
Drug Hypersensitivity
1
2000
83
0.040
 Why?
Kidney Function Tests
1
2019
164
0.040
 Why?
Child
2
2017
19129
0.040
 Why?
Societies, Scientific
1
2019
49
0.040
 Why?
Blood Coagulation
1
2000
219
0.040
 Why?
Software
1
2023
613
0.040
 Why?
Student Health Services
1
2018
16
0.040
 Why?
United States Department of Veterans Affairs
1
2022
555
0.040
 Why?
Self Care
1
2000
357
0.040
 Why?
Antiretroviral Therapy, Highly Active
1
1999
260
0.040
 Why?
Cross-Sectional Studies
2
2021
4552
0.040
 Why?
Glucose
1
2022
953
0.040
 Why?
Hospitals
1
2022
598
0.040
 Why?
Homozygote
1
2017
190
0.040
 Why?
Felodipine
1
1996
4
0.040
 Why?
Receptors, Drug
1
1996
13
0.040
 Why?
Public Health
1
2021
450
0.040
 Why?
Cost-Benefit Analysis
1
2019
554
0.040
 Why?
Polypharmacy
1
2016
75
0.030
 Why?
Cross-Over Studies
1
1997
456
0.030
 Why?
Patient Discharge
1
2022
796
0.030
 Why?
Calcium Channels
1
1996
150
0.030
 Why?
Internet
1
1999
633
0.030
 Why?
Communication
2
2014
761
0.030
 Why?
Medication Adherence
2
2010
556
0.030
 Why?
Antibodies, Monoclonal, Humanized
1
2019
667
0.030
 Why?
Myocardial Ischemia
1
1996
251
0.030
 Why?
Data Interpretation, Statistical
1
1996
336
0.030
 Why?
Regression Analysis
2
2009
983
0.030
 Why?
Clinical Decision-Making
1
2016
278
0.030
 Why?
Pain
1
1999
735
0.030
 Why?
Infant
2
2004
8293
0.030
 Why?
Pandemics
1
2021
1355
0.030
 Why?
Hemodynamics
1
1997
1004
0.030
 Why?
Comprehension
1
2014
163
0.030
 Why?
Adrenergic Antagonists
1
2011
9
0.030
 Why?
Renin
1
2011
35
0.030
 Why?
Educational Status
1
2014
437
0.030
 Why?
Prospective Studies
3
2015
6471
0.020
 Why?
Phytotherapy
1
2011
69
0.020
 Why?
Health Planning Guidelines
1
2010
25
0.020
 Why?
Breast Neoplasms
1
2003
1965
0.020
 Why?
Anti-Bacterial Agents
1
2000
1510
0.020
 Why?
Drug Utilization
1
2011
169
0.020
 Why?
Poisson Distribution
1
2010
68
0.020
 Why?
Pilot Projects
1
2015
1419
0.020
 Why?
Likelihood Functions
1
2010
136
0.020
 Why?
Models, Organizational
1
2011
146
0.020
 Why?
Preferred Provider Organizations
1
2009
5
0.020
 Why?
Transportation
1
2009
42
0.020
 Why?
Case-Control Studies
1
2016
3171
0.020
 Why?
Private Sector
1
2009
51
0.020
 Why?
Phenotype
1
2017
3003
0.020
 Why?
Infliximab
1
2009
94
0.020
 Why?
Interprofessional Relations
1
2011
261
0.020
 Why?
North America
1
2009
266
0.020
 Why?
Quality of Life
1
2019
2366
0.020
 Why?
Cooperative Behavior
1
2011
408
0.020
 Why?
Multivariate Analysis
1
2010
1474
0.020
 Why?
Organizational Policy
1
2006
70
0.020
 Why?
Professional Practice
1
2006
62
0.020
 Why?
Health Care Costs
1
2009
394
0.020
 Why?
Time Factors
1
1996
6412
0.020
 Why?
Role
1
2005
32
0.020
 Why?
Logistic Models
1
2010
1901
0.020
 Why?
Bone Diseases, Metabolic
1
2005
60
0.020
 Why?
Interdisciplinary Communication
1
2005
191
0.010
 Why?
Models, Economic
1
2004
48
0.010
 Why?
Review Literature as Topic
1
2004
68
0.010
 Why?
Diabetes Complications
1
2005
218
0.010
 Why?
Probability
1
2004
305
0.010
 Why?
Venlafaxine Hydrochloride
1
2002
12
0.010
 Why?
Menstruation
1
2002
36
0.010
 Why?
International Normalized Ratio
1
2000
45
0.010
 Why?
Health Maintenance Organizations
1
2000
96
0.010
 Why?
beta-Lactams
1
2000
28
0.010
 Why?
Hospitalization
1
2009
1785
0.010
 Why?
Medical Records
1
2000
163
0.010
 Why?
Sensitivity and Specificity
1
2004
1795
0.010
 Why?
Depressive Disorder
1
2002
333
0.010
 Why?
Prevalence
1
2005
2326
0.010
 Why?
Depression
1
2004
1132
0.010
 Why?
Saseen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (451) concept(s)
_
Co-Authors Expand Description
See all (42) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)